TScan Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
TScan Therapeutics Free Cash Flow (FCF) History (TCRX)
TScan Therapeutics reported −$139.7M in free cash flow for fiscal 2025, a decrease of $25.1M from the previous fiscal year, with a free cash flow margin of −1353.28%.
View full TScan Therapeutics company overviewTScan Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$139.7M | −$25.1M | — | −1353.28% |
| 2024 | 2024-12-31 | −$114.6M | −$50.1M | — | −4071.27% |
| 2023 | 2023-12-31 | −$64.5M | $6.2M | — | −306.45% |
| 2022 | 2022-12-31 | −$70.7M | −$12.1M | — | −522.56% |
| 2021 | 2021-12-31 | −$58.6M | −$51.4M | — | −578.03% |
| 2020 | 2020-12-31 | −$7.3M | — | — | −669.22% |
TScan Therapeutics quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$28.0M | $6.5M | — | −2666.79% |
| Q1 2026 | 2026-03-31 | −$24.3M | $14.8M | — | −2479.53% |
| Q4 2025 | 2025-12-31 | −$32.2M | −$3.9M | — | −1253.33% |
| Q3 2025 | 2025-09-30 | −$33.9M | −$4.6M | — | −1349.62% |
| Q2 2025 | 2025-06-30 | −$34.5M | −$7.5M | — | −1123.08% |
| Q1 2025 | 2025-03-31 | −$39.1M | −$9.1M | — | −1801.84% |
| Q4 2024 | 2024-12-31 | −$28.3M | −$4.1M | — | −4255.64% |
| Q3 2024 | 2024-09-30 | −$29.3M | −$35.9M | — | −2791.99% |
| Q2 2024 | 2024-06-30 | −$27.1M | −$4.6M | — | −5053.54% |
| Q1 2024 | 2024-03-31 | −$30.0M | −$5.5M | — | −5295.41% |
| Q4 2023 | 2023-12-31 | −$24.2M | −$6.8M | — | −336.08% |
| Q3 2023 | 2023-09-30 | $6.6M | $24.0M | — | +169.75% |
| Q2 2023 | 2023-06-30 | −$22.4M | −$7.2M | — | −712.90% |
| Q1 2023 | 2023-03-31 | −$24.4M | −$3.8M | — | −359.03% |
| Q4 2022 | 2022-12-31 | −$17.4M | −$796,000 | — | −561.78% |
| Q3 2022 | 2022-09-30 | −$17.4M | −$2.9M | — | −518.17% |
| Q2 2022 | 2022-06-30 | −$15.3M | −$642,000 | — | −376.23% |
| Q1 2022 | 2022-03-31 | −$20.7M | −$7.7M | — | −683.71% |
| Q4 2021 | 2021-12-31 | −$16.6M | −$9.5M | — | −581.32% |
| Q3 2021 | 2021-09-30 | −$14.5M | — | — | −600.87% |
| Q2 2021 | 2021-06-30 | −$14.6M | — | — | −513.27% |
| Q1 2021 | 2021-03-31 | −$12.9M | — | — | −637.20% |
| Q3 2020 | 2020-09-30 | −$7.1M | — | — | −2459.31% |
TScan Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$7.3M to −$139.7M, a net decrease of $132.5M. TScan Therapeutics's latest reported quarter, Q2 2026, generated −$28.0M in free cash flow, an increase of $6.5M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review TScan Therapeutics filings at SEC.gov ↗